A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT ID: NCT04464798

Last Updated: 2025-04-29

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-11
• Study Completion Date: 2025-01-09

Brief Summary

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification.

Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).

Conditions

Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort A- Monotherapy in R/R lymphoma subjects

Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects

Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.

• Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.
• Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC administration at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2.

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Rituximab

Intervention Type: DRUG

SC and IV infusion

Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects

Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.

• Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
• Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6.

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Obinutuzumab

Intervention Type: DRUG

IV Infusion

Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphoma

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphoma

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Rituximab

Intervention Type: DRUG

SC and IV infusion

Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3a

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Rituximab

Intervention Type: DRUG

SC and IV infusion

Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3a

Group Type: EXPERIMENTAL

CC-220

Intervention Type: DRUG

Oral

Obinutuzumab

Intervention Type: DRUG

IV Infusion

Interventions

CC-220

Oral

Intervention Type: DRUG

Rituximab

SC and IV infusion

Intervention Type: DRUG

Obinutuzumab

IV Infusion

Intervention Type: DRUG

Other Intervention Names

Iberdomide

Eligibility Criteria

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

1. Is ≥ 18 years of age at the time of signing the informed consent form (ICF).

2. Has histologically confirmed (per local evaluation) diagnosis of lymphoma according to 2016 World Health Organization (WHO) classification including:

1. Cohort A: all subtypes including B-cell, T-cell and Natural killer (NK)-cell Non-Hodgkin lymphoma (NHL), and Classical Hodgkin lymphoma (cHL).

2. Cohort B: all B-cell NHL.

3. Cohort C: FL Grade 1-3a and MZL including extranodal marginal zone lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL)

4. Cohort D: aggressive B-cell lymphoma and FL grade 1-3a

5. Cohort E: aggressive B-cell lymphoma including DLBCL NOS, high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements, Grade 3b FL and PMBCL

6. Cohorts F and G: FL Grade 1 to 3a

3. Relapsed or refractory disease according to the following definitions:

1. Aggressive B-cell lymphoma

2. Follicular lymphoma (FL) and Marginal zone lymphoma (MZL): following at least 2 prior lines of systemic therapy (being previously exposed to at least 1 anti-CD20 mAb and 1 alkylating agent).

3. Mantle cell lymphoma (MCL): following at least 2 prior lines of therapy including at least 1 immunochemotherapy and 1 bruton tyrosine kinase (BTK) inhibitor.

4. Peripheral T-cell lymphoma (PTCL): following at least 2 prior lines of therapy OR after 1 prior line of standard therapy and being not eligible for any other approved regimen.

5. Classical Hodgkin lymphoma (cHL): following at least 2 prior systemic lines of therapy and previously exposed to brentuximab vedotin and anti-PD1.

6. All other subtypes: following at least 2 prior lines of therapy.

7. Subjects previously treated with CAR-T therapy can be enrolled (irrespective of the indication).

4. Subjects must not be eligible for any other approved treatment for their underlying lymphoma as assessed by the Investigator.

5. Must have measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification. Site of measurable disease cannot be previously irradiated.

6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

7. Must have the following laboratory values:

1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L

2. Hemoglobin (Hb) ≥ 8 g/dL.

3. Platelets (Plt) ≥ 75 x 109/L or ≥ 50 x 109/L

4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN.

5. Serum total bilirubin ≤ 1.5 ULN except in cases of Gilbert's syndrome, then ≤ 3.0 ULN.

6. Estimated serum creatinine clearance of ≥ 50 mL/min

8. All subjects must:

1. Have an understanding that the study drug could have a potential teratogenic risk.

2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.

9. Females of childbearing potential (FCBP1) must:

a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.

10. Male subjects must:

1. Practice true abstinence2 or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study,

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

1. Any significant medical condition, active infection (including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2) suspected or confirmed, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Life expectancy ≤ 3 months.

4. Diagnosis of lymphoblastic lymphoma.

5. Aggressive lymphoma relapse requiring immediate cytoreductive therapy to avoid potential life-threatening consequences (eg, due to tumor location).

6. Prior Grade 3 or 4 infusion related reaction with rituximab (for Cohorts B, E and F) or obinutuzumab (for Cohorts C and G).

7. Prior therapy with the cereblon-modulating drug CC-99282.

8. Chronic systemic immunosuppressive therapy or corticosteroids.

9. Prior ASCT ≤ 3 months prior to starting CC-220 or > 3 months AND with unresolved, Grade > 1, treatment-related toxicity.

10. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-220 or > 6 months with unresolved, Grade > 1, treatment-related toxicity.

11. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or obinutuzumab.

12. Known allergy to thalidomide, pomalidomide or lenalidomide.

13. Inability or unwilling to undergo protocol required thromboembolism prophylaxis.

14. Major surgery ≤ 2 weeks prior to starting CC-220;

15. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).

16. Documented or suspected central nervous system (CNS) involvement of disease.

17. Subject with clinically significant cardiac disease.

18. Known seropositivity for or active viral infection with human immunodeficiency virus (HIV).

19. Known chronic active hepatitis B

20. History of other malignancy, unless the subject has been free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:

1. Incidental histologic finding of prostate cancer (or prostate cancer that has been treated with curative intent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Local Institution - 106

Phoenix, Arizona, United States

Local Institution - 105

Lake Mary, Florida, United States

Local Institution - 102

Rochester, Minnesota, United States

Local Institution - 100

New York, New York, United States

University of Rochester Cancer Center

Rochester, New York, United States

Local Institution - 103

Nashville, Tennessee, United States

Local Institution - 203

Créteil, , France

Local Institution - 200

Lillie Cedex, , France

Local Institution - 201

Montpellier, , France

Local Institution - 202

Nantes, , France

Local Institution - 204

Paris, , France

Local Institution - 205

Pessac, , France

Local Institution - 401

Berlin, , Germany

Local Institution - 402

Leipzig, , Germany

Local Institution - 403

Münster, , Germany

Local Institution - 404

Würzburg, , Germany

Local Institution - 300

Brescia, , Italy

Local Institution - 303

Milan, , Italy

Local Institution - 301

Pavia, , Italy

Local Institution - 302

Verona, , Italy

Local Institution - 502

Seoul, , South Korea

Local Institution - 501

Seoul, , South Korea

Local Institution - 500

Seoul, , South Korea

Local Institution - 600

Niaosong District Kaohsiung City, , Taiwan

Local Institution - 601

Taoyuan, , Taiwan

Local Institution - 602

Taoyuan, , Taiwan

Countries

United States; France; Germany; Italy; South Korea; Taiwan

Related Links

https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

BMS Clinical Trial Information

http://www.BMSClinicalTrials.com

BMS Clinical Trial Patient Recruiting

Other Identifiers

U1111-1254-1772

Identifier Type: REGISTRY

Identifier Source: secondary_id

2020-000354-10

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CC-220-NHL-001

Identifier Type: -

Identifier Source: org_study_id